Over a million women worldwide are diagnosed with breast cancer annually. Alongside surgery, radiotherapy and immunotherapy, pharmaceutical products (including hormonal therapy and chemotherapy) are in the frontline against this terrible disease. Market reports in this section enable buyers to read up on the latest breast cancer drug pipelines and R&D strategies, as well as the medical and commercial activities of major players and niche operators such Abraxis Bioscience, Aeterna Zentaris, Agendia
BV, Aphton Corp, Array BioPharma, AstraZeneca Plc, Bristol Myers Squibb, Dendreon Corporation, Eli Lilly, Genentech, Genta, Novartis AG, Pfizer, Roche Group, Sanofi-Aventis, Schering AG, Therion Biologics, and ViRexx Medical. Also included are cutting edge academic journals and various expert textbooks for medical professionals involved in breast cancer treatment.